Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

NIH 19OTHER 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Biphenotypic, Acute 6Leukemia, Myeloid, Acute 5Carcinoma, Non-Small-Cell Lung 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lung Neoplasms 4Burkitt Lymphoma 4Wilms Tumor 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Osteosarcoma 3Neuroblastoma 3Ganglioneuroblastoma 3Teratoma 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Hepatoblastoma 2Hematologic Neoplasms 2Fibrolamellar hepatocellular carcinoma 2Desmoid Tumors 2Carcinoma, Embryonal 2Anatomic Stage I Breast Cancer AJCC v8 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Rhabdomyosarcoma, Embryonal 1

Interventions

Cyclophosphamide 50Vincristine 49Doxorubicin 44Prednisone 42Rituximab 32Radiotherapy 27Etoposide 27Methotrexate 24Filgrastim 24Cytarabine 23Dexamethasone 15Granulocyte Colony-Stimulating Factor 13Bleomycin 13Vinblastine 12Peripheral Blood Stem Cell Transplantation 12Leucovorin 11Gene Expression Profiling 10Bortezomib 10Immunohistochemistry 9Procarbazine 8Polymerase Chain Reaction 8Gemcitabine 8Melphalan 7Amplified Fragment Length Polymorphism Analysis 7VAP-cyclo protocol 6Mercaptopurine 6Ifosfamide 6Dacarbazine 6Carmustine 6Microarray Analysis 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Lymphoma × Specimen Handling × Clear all
NCT04870944 2026-05-05

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Children's Oncology Group

Phase 1/2 Recruiting
63 enrolled
CNSLymphoid

Diffuse Intrinsic Pontine Glioma, Lymphoma

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡